Title:
APPLICATION OF ABT-263 IN PREPARATION OF DRUG FOR INHIBITING CORNEAL TRANSPLANT IMMUNE REJECTION
Document Type and Number:
WIPO Patent Application WO/2023/024664
Kind Code:
A1
Abstract:
The present invention relates to the technical field of chemical drugs and provides an application of ABT-263 in the preparation of a drug for inhibiting corneal transplantation immune rejection. The present invention provides an application of a small-molecule Bcl-2 inhibitor Navitoclax (ABT-263), which is capable of inducing apoptosis, in the preparation of a product for inhibiting immune rejection after a corneal transplant. According to the present invention, researches show that the Bcl-2 inhibitor ABT-263 can prolong the survival time of a corneal implant after a corneal transplant, reduce the immune inflammatory response in the corneal implant, maintain the transparency of the corneal implant, reduce the immune rejection, and can be used in prevention and treatment of diseases such as immune rejection and corneal endothelial cell decompensation after a corneal transplant.
More Like This:
Inventors:
SHI WEIYUN (CN)
WEI CHAO (CN)
CHI HAO (CN)
YIN WENHUI (CN)
BAI XIAOFEI (CN)
WEI CHAO (CN)
CHI HAO (CN)
YIN WENHUI (CN)
BAI XIAOFEI (CN)
Application Number:
PCT/CN2022/099063
Publication Date:
March 02, 2023
Filing Date:
June 16, 2022
Export Citation:
Assignee:
EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIV (CN)
International Classes:
A61K31/5377; A61P37/06; A61K9/08
Domestic Patent References:
| WO2020214993A1 | 2020-10-22 |
Foreign References:
| CN113633642A | 2021-11-12 | |||
| JP2020111548A | 2020-07-27 | |||
| US20080182845A1 | 2008-07-31 | |||
| CN107921031A | 2018-04-17 | |||
| CN105377289A | 2016-03-02 | |||
| CN101595107A | 2009-12-02 |
Other References:
YIN, WENHUI: "The Effect of Corneal Graft Senescence after Corneal Transplantation on Allograft Rejection and Its Mechanism", MEDICINE AND HEALTH SCIENCES, CHINA DOCTORAL DISSERTATIONS/MASTER'S THESES FULL-TEXT DATABASE (MASTER), vol. 2021, no. 1,, 1 January 2020 (2020-01-01), CN, pages 1 - 51, XP009544022, DOI: 10.27262/d.cnki.gqdau.2020.000965
YAMANE MIO, SATO SHINRI, SHIMIZU EISUKE, SHIBATA SHINSUKE, HAYANO MOTOSHI, YAGUCHI TOMONORI, KAMIJUKU HAJIME, OGAWA MAMORU, SUZUKI: "Senescence‐associated secretory phenotype promotes chronic ocular graft‐vs‐host disease in mice and humans", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 34, no. 8, 1 August 2020 (2020-08-01), US, pages 10778 - 10800, XP093038715, ISSN: 0892-6638, DOI: 10.1096/fj.201900218R
KIRKLAND J. L. ET AL.: "Senolytic drugs: from discovery to translation", JOURNAL OF INTERNAL MEDICINE, vol. 288, no. 5, 19 July 2020 (2020-07-19), XP055746771, ISSN: 0954-6820, DOI: 10.1111/joim.13141
YAMANE MIO, SATO SHINRI, SHIMIZU EISUKE, SHIBATA SHINSUKE, HAYANO MOTOSHI, YAGUCHI TOMONORI, KAMIJUKU HAJIME, OGAWA MAMORU, SUZUKI: "Senescence‐associated secretory phenotype promotes chronic ocular graft‐vs‐host disease in mice and humans", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 34, no. 8, 1 August 2020 (2020-08-01), US, pages 10778 - 10800, XP093038715, ISSN: 0892-6638, DOI: 10.1096/fj.201900218R
KIRKLAND J. L. ET AL.: "Senolytic drugs: from discovery to translation", JOURNAL OF INTERNAL MEDICINE, vol. 288, no. 5, 19 July 2020 (2020-07-19), XP055746771, ISSN: 0954-6820, DOI: 10.1111/joim.13141
Attorney, Agent or Firm:
BEIJING YICHUANMING INTELLECTUAL PROPERTY AGENCY (SPECIAL GENERAL PARTNERSHIP) (CN)
Download PDF: